OBIO Stock Analysis: Buy, Sell, or Hold?
OBIO - Orchestra BioMed Holdings, Inc. Ordinary Shares
$5.36
-0.07 (-1.29%)
▼
5d:
+21.54%
30d:
+47.25%
90d:
+30.73%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Get Alerted When OBIO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: OBIO is 19.1% above its trading range ($4.50). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: OBIO is 19.1% above its trading range ($4.50). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: OBIO is currently trading at $5.36, which is considered extended relative to its 30-day fair value range of $3.63 to $4.50.
Technical Outlook: Technically, OBIO is showing sideways momentum. Immediate support is located at $4.20, while resistance sits at $5.78.
Market Sentiment: OBIO scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $12.33 (+130.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, OBIO is showing sideways momentum. Immediate support is located at $4.20, while resistance sits at $5.78.
Market Sentiment: OBIO scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $12.33 (+130.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$3.63 -
$4.50
Company Quality Score
33/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
15.8%
All Signals
- BEARISH: Price significantly overextended (+19.1% above its trading range)
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 130.1% below Wall St target ($12.33)
- WARNING: Composite score 33/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.63 -
$4.50
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$4.20
Resistance Level
$5.78
Current Trend
Sideways
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.54
Wall Street Target
$12.33
(+130.1%)
Revenue Growth (YoY)
-89.5%
Profit Margin
-184.6%
Share & Embed Analysis
Last updated: August 22, 2026 9:47 PM ET
Data refreshes hourly during market hours. Next update: 10:47 PM
Data refreshes hourly during market hours. Next update: 10:47 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OBIO showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
David P Hochman
BUY
10000 shares
2026-03-13
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$372 | 42 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 27 SELL |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$563 | 30 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$309 | 51 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 50 HOLD |
